Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration
(FDA) for the treatment of multiple myeloma for patients who have received at least one prior
therapy. Velcade is a unique compound developed by scientists at Millennium Pharmaceuticals,
Inc. Velcade enters cells and affects the way they divide. Cancer cells are particularly
sensitive. Velcade interferes with the enzyme "proteasome" which is responsible for allowing
cells to divide. When cancer cells cannot divide, they die. Velcade falls into the class of
drugs known as "proteasome inhibitors."